Remove 2028 Remove Drug Development Remove Process Improvement
article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

Inclusion of Part B Drugs: Scope, Challenges, and Opportunities The addition of provider-administered therapies covered under Medicare Part B to the IPAY 2028 cycle introduces a fundamentally different reimbursement and care delivery context than that of pharmacy-dispensed Part D drugs.

article thumbnail

Understanding Large Molecule Drug Development: From Biologics to Market

Syner-G

Cell Line Development Demand for biologics has impacted the cell line development (CLD) market, expected to reach $1.7 billion by 2028. Both processes are evolving to enhance product development and output.